ALK-Abello Q4 earnings surpass expectations, dividend raised

Investing.com – ALK-Abello A/S (CSE:ALKB) announced its Q4 earnings on Friday, surpassing analyst expectations with sales reaching 1.73 billion Danish kroner, up 3% from the consensus estimate of 1.69 billion Danish kroner.

The Danish biotech company’s EBITDA was 387 million Danish kroner, exceeding the market consensus of 370 million Danish kroner by 5%.

The sales beat expectations primarily due to strong performance in the European tablet business, which was 6% above forecasts, while other products outperformed by 14%. Overall tablet sales were 2% higher than expected, while subcutaneous injections and sublingual immunotherapy drops met expectations, totaling 607 million Danish kroner.

The company’s EBITDA margin reached 22.3%, above the market consensus of 21.9%. The improved gross margin was partly offset by higher operating expenses, and higher taxes resulted in net profit falling below expectations.

ALK-Abello proposed a dividend of 1.6 Danish kroner per share, marking the first dividend since 2017. The dividend reflects the company’s current net debt position.

For 2026, ALK-Abello provided an revenue guidance of 11% to 15% growth at constant exchange rates, implying revenue between 6.9 billion and 7.2 billion Danish kroner. The market consensus was 7.04 billion Danish kroner, about 40 to 70 basis points below the midpoint of the guidance range.

The company expects an EBITDA margin of around 25% in 2026, in line with analyst forecasts. Margins are expected to decline slightly as the favorable impact from growth in European tablet sales will be offset by sales related to partners with lower profit margins.

Regarding other products, the company’s Neffy product performed well in Germany, where it gained reimbursement status and captured an 18% value share within six months. However, approval times in Canada were slightly longer than initially expected.

ALK-Abello announced that Henriette Mersebach will step down as Head of R&D on February 23, with both parties agreeing to seek candidates with different backgrounds.

Former R&D head Henrik Jacobi has been appointed as CEO and special advisor to the executive team. The company has initiated the recruitment process for a new R&D leader.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.